TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03921034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine
Description: All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
Study: NCT00929552

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary oils (fish, vegetable oil)
Description: 6g pr day.
Study: NCT03921034

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
Study: NCT01954641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACCURE Navigator
Description: The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the teachback method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care by Cancer Center Care Team
Description: The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
Study: NCT03742973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT02999516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imaginary
Description: Participants imagine doing a motor task watching a video recording
Study: NCT02233634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperventilation Breath-hold (HVBH)
Description: 1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperventilation Breath-hold (HVBH)
Description: 1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVBH with Oxygen
Description: 1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVBH with Oxygen
Description: 1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
Study: NCT04612166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Action Plan and Patient Empowerment (MAP-PE )
Description: Intervention patients (after consenting) will meet with a study health coach for an in-person meeting where the health coach will review the pharmacists Medication Action Plan (MAP) for deprescription of high-risk medication. The MAP will have previously been approved by both the patient and the patient's primary care physician. If the patient is on more than one high risk medication, the medication that puts them at the highest risk will be deprescribed first and only one medication will be decreased at a time. During this initial meeting, the health coach will use motivational interviewing and distribute materials to empower and support the patient in the reduction of the medication as outlined on their MAP. The health coach will then follow up with the patient on a schedule determined~by the type and dosage of medication being reduced. Follow ups will decrease in frequency over time (starting with at least once a week). The patients will be followed for up to 12 months.
Study: NCT02011100

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnosine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carnosine
Study: NCT02028533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02999516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Motor imaginary
Description: Participants watch a television documentary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS sham
Description: tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback sham
Description: EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
Study: NCT00620776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Description: Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
Study: NCT04000958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIRF measured by InCheck DIAL
Description: Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular treament
Description: The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
Study: NCT02059226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioural therapy
Description: Internet-based CBT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based resource page
Description: Static webpage
Study: NCT03547310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyoBeatz
Description: Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
Study: NCT02304523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFR0612
Description: Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFR0613
Description: Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coolprep Powder
Description: Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Study: NCT02296567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control group Subjects will no previous anti-VEGF treatment
Study: NCT03116711

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive CIQ plus High Carbohydrate Diet
Description: Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive CIQ plus High Protein Diet
Description: Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative CIQ plus High Carbohydrate Diet
Description: Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative CIQ plus High Protein Diet
Description: Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
Study: NCT00952458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Description: Neuromonitoring of depth of sedation with Bispectral Index
Study: NCT03391661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education patient exercise
Description: Patients complete a 15 to 20-minute on-line exercise that inquires about 5 domains: the degree of central sensitization symptoms, catastrophizing and kinesiophobia, personality factors, stressors that triggered or exacerbated the pain, and adverse childhood experiences.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health behavior control intervention
Description: Patients engage in a 15 to 20-minute on-line exercise examining their health behaviors in five domains: exercise, sleep, diet, hygiene, and social connections.
Study: NCT04410094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules will be administered orally.
Study: NCT00580723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRK 124
Description: Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
Study: NCT04995575

Intervention type: PROCEDURE
Intervention: collection of the biopsy, blood samples
Description: for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals.~For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples
Study: NCT00556998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
Study: NCT03997526

Intervention type: DEVICE
Intervention: 3C Patch
Description: A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process
Study: NCT03707301

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
Study: NCT01982123

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation and post-radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Albumin Aggregated
Description: Undergo 99mTc-MAA SPECT/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m DTPA
Description: Undergo 99mTc-DTPA SPECT/CT
Study: NCT02426515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hilotherm® cooling device and face mask
Description: Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
Study: NCT00880698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq
Description: 2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IUs per aggregate dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq
Description: 2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IUs per aggregate dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL solution
Study: NCT01112397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480
Description: continuous daily oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480
Description: continuous daily oral capsule
Study: NCT03591926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04646
Description: Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04646
Description: Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week.
Study: NCT00694655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.
Study: NCT00675909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized Intranasal midazolam
Description: Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized Buccal Midazolam
Description: 0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: oral midazolam 0.5mg/kg
Study: NCT03811444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haemolance Plus safety lancet
Description: Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance safety lancet
Description: Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSafe Solo safety lancet
Description: MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
Study: NCT02392130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 130852A gel 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 130852A placebo gel